Manufacturers benefited from regulatory flexibilities that allowed them to get COVID-19 products on the market at lightening speed. But they could face government enforcement actions and litigation once the public health emergency ends and emergency use authorizations (EUAs) for their products are terminated.
“In a post-COVID pandemic world, that period of flexibility and the sense of collective urgency will eventually draw to a...





